Cellular Mechanism of Action
The primary site of action is the GABA-A receptor complex. The active substance binds to specific "barbiturate" sites on this receptor. This interaction induces allosteric conformational changes in the receptor, sharply increasing its sensitivity to the principal inhibitory neurotransmitter — gamma-aminobutyric acid (GABA).
As a consequence of this process, there is an increased influx of negatively charged chloride ions ($Cl^-$) into the neuron. This results in cell membrane hyperpolarization, leading to a significant reduction in the excitability of nerve cells, particularly within the epileptogenic focus.
In addition, secondary mechanisms are proposed:
- Alteration of membrane permeability to other important ions: sodium ($Na^+$), potassium ($K^+$), and calcium ($Ca^{2+}$).
- Antagonism toward glutamate, the main excitatory neurotransmitter in the central nervous system.
Pharmacological Effects and Indications
The anticonvulsant properties of this compound have been utilized in medicine since 1910. Along with its antiepileptic effect, the substance exerts strong sedative and hypnotic actions. In clinical practice for epilepsy, the drug is administered in subhypnotic doses, though sedation very frequently persists as a background adverse effect.
Main indications for use:
- Prevention of generalized tonic-clonic seizures.
- Prophylaxis of focal (partial) seizures.
- Acute management of status epilepticus.
It is available in several dosage forms. For planned prophylactic oral administration, tablets and solutions are used. For the emergency management of status epilepticus, intravenous administration (as the sodium salt) is employed.
Pharmacokinetics
Upon oral administration, the drug is absorbed completely, though relatively slowly. Peak plasma concentration ($T_{max}$) is reached in 1–2 hours. The substance binds to plasma proteins by approximately 50%, after which it slowly and evenly distributes into body tissues and organs.
Metabolism occurs in the liver, yielding the inactive metabolite 4-hydroxyphenobarbital. A crucial feature is that it acts as a potent inducer of hepatic microsomal enzymes. Consequently, it accelerates the clearance of other medications and triggers autoinduction (accelerating its own metabolism).
Elimination is carried out by the kidneys as a glucuronide conjugate, with about 25% of the drug excreted unchanged. The elimination half-life ($t_{1/2}$) is very long: 2–4 days in adults and up to 7 days in newborns. This accounts for a pronounced cumulative effect — the ability of the drug to accumulate in the body with regular intake.
Adverse Effects and Contraindications
Due to its prolonged persistence in the body and high potential for accumulation, therapy is frequently accompanied by adverse reactions:
- Central nervous system: persistent somnolence, ataxia, lethargy, and depressive symptoms.
- Somatic manifestations: arterial hypotension, nausea, and vomiting.
- Allergic reactions: skin rashes.
Long-term continuous use leads to the development of drug dependence and tolerance (habituation, where higher doses are required to achieve the initial effect).
Administration is strictly contraindicated during pregnancy and lactation, in severe hepatic and renal impairment, myasthenia gravis, and established hypersensitivity to barbiturates.
Related Anticonvulsant Agents
This pharmacological group includes other barbituric acid derivatives and structurally related compounds:
- Benzobarbital (Benzonal). Used for the prevention of generalized tonic-clonic seizures. It shares a barbiturate-like profile of adverse effects (somnolence, headache, ataxia, speech disorders, and weakness).
- Primidone (Hexamidine). Chemically a pyrimidine derivative, but structurally very similar to the main drug. It is also used to prevent major seizures, though it offers an important advantage: it is less toxic and causes significantly less somnolence.